Durable Responses to Anti-PD1 and Anti-CTLA4 in a Preclinical Model of Melanoma Displaying Key Immunotherapy Response Biomarkers
Immunotherapy has transformed the management of patients with advanced melanoma, with five-year overall survival rates reaching 52% for combination immunotherapies blocking the cytotoxic T-lymphocyte-associated antigen-4 (CTLA4) and programmed cell death-1 (PD1) immune axes. Yet, our understanding o...
Main Authors: | Elena Shklovskaya, Bernadette Pedersen, Ashleigh Stewart, Jack O. G. Simpson, Zizhen Ming, Mal Irvine, Richard A. Scolyer, Georgina V. Long, Helen Rizos |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-10-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/19/4830 |
Similar Items
-
MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It
by: Elena Shklovskaya, et al.
Published: (2021-06-01) -
Tumor MHC Expression Guides First-Line Immunotherapy Selection in Melanoma
by: Elena Shklovskaya, et al.
Published: (2020-11-01) -
Use of Dendritic Cell Receptors as Targets for Enhancing Anti-Cancer Immune Responses
by: Md Kamal Hossain, et al.
Published: (2019-03-01) -
MHC-I genotype and tumor mutational burden predict response to immunotherapy
by: Aaron M. Goodman, et al.
Published: (2020-05-01) -
Hilliard Seigler, M.D. and the origins of kidney transplantation and immunology at Duke
by: Stuart J. Knechtle, et al.
Published: (2023-05-01)